Liquidia Corporation Stock Price, News & Analysis

Liquidia Technologies has appointed Dr. Gerald M. O’Brien as Vice President of Pulmonary Clinical Development, effective immediately. With 25 years of experience in pulmonary critical care, Dr. O’Brien aims to enhance Liquidia's efforts in treating pulmonary arterial hypertension (PAH). Previously, he led the PRIMEx trial at Complexa Inc. Liquidia focuses on developing innovative products using its proprietary PRINT® technology, specifically for PAH and post-operative pain management.

Liquidia Technologies (NASDAQ: LQDA) has announced a special meeting for stockholders on October 21, 2020, to vote on the acquisition of RareGen, LLC, following the SEC's approval of the registration statement relating to the merger. Stockholders as of September 14, 2020, are eligible to vote. CEO Neal Fowler emphasized the strategic importance of the acquisition, which aims to benefit shareholders and enhance treatment options for pulmonary arterial hypertension patients. The transaction remains subject to customary closing conditions and stockholder approval.

Liquidia Technologies (NASDAQ: LQDA) announced receiving a Notice of Allowance from the USPTO for a patent application related to LIQ861, a dry powder treprostinil under FDA review for pulmonary arterial hypertension. This patent is expected to enhance Liquidia's intellectual property position and is a vital step towards commercialization. The patent is anticipated to be issued in Q4 2020, with a term extending until 2037. This development signals Liquidia's commitment to addressing unmet needs in PAH treatment.

Liquidia Technologies (NASDAQ: LQDA) has appointed Steven Bariahtaris as interim Chief Financial Officer following the resignation of Richard Katz. Bariahtaris brings nearly 24 years of experience from Johnson & Johnson, where he held several executive roles. His appointment comes as Liquidia prepares for the acquisition of RareGen and the potential launch of LIQ861, aimed at treating pulmonary arterial hypertension. CEO Neal Fowler emphasized Bariahtaris's strategic insights and financial expertise as crucial for the company's growth during this transformative period.

Liquidia Technologies (LQDA) has received FDA acceptance for its New Drug Application (NDA) for LIQ861, targeting pulmonary arterial hypertension (PAH), with a Prescription Drug User Fee Act (PDUFA) goal date set for November 24, 2020. The company reported no revenues for Q2 2020, a decrease from $8.1 million in Q2 2019, resulting in a net loss of $13.9 million. R&D expenses decreased while G&A expenses rose significantly due to legal costs associated with the RareGen acquisition. Liquidia raised $75 million from a public offering and appointed Tushar Shah, M.D. as Chief Medical Officer.

Liquidia Technologies (Nasdaq: LQDA) will have its CEO, Neal Fowler, present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 10:20 AM ET. The event will highlight Liquidia's focus on developing novel biopharmaceutical products using its proprietary PRINT® technology, aimed at enhancing patient outcomes. Liquidia is currently developing two primary candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for postoperative pain. A live audio webcast will be available for attendees.

Liquidia Technologies (LQDA) reported exploratory endpoint data from the INSPIRE study of LIQ861 for pulmonary arterial hypertension (PAH) during the ATS Annual Meeting. LIQ861, an inhaled dry powder formulation, showed improvements after two months, including increased six-minute walk distance and reduced Minnesota LIVING WITH HEART FAILURE Questionnaire scores. Over 70% of subjects titrated to higher doses, with 93% tolerating the treatment well. Liquidia has submitted a New Drug Application for LIQ861, awaiting FDA review by November 24, 2020.

Liquidia Technologies (Nasdaq: LQDA) announced plans to release its second quarter 2020 financial results on August 10, 2020. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide corporate updates. The company focuses on developing novel therapeutics using its proprietary PRINT® technology, primarily targeting pulmonary arterial hypertension (PAH) with its product candidate LIQ861 and local post-operative pain with LIQ865. Liquidia aims to improve patient outcomes through precise drug particle production.

Liquidia Technologies (LQDA) announced an amended complaint from United Therapeutics Corporation regarding alleged patent infringement related to its pulmonary arterial hypertension treatment, LIQ861. The original complaint, filed in June 2020, triggered a 30-month regulatory stay on LIQ861's FDA approval. However, the new patent allegations do not affect the review timeline. Liquidia asserts that LIQ861 offers a beneficial treatment option for patients, and the company is committed to defending its position vigorously.